TriangleHEALTH PROFESSIONAL · SOURCE READING
Chemotherapy
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Promising results have been observed with the addition of carboplatin to anthracycline/taxane combination chemotherapy regimens in patients with TNBC.
Evidence (adding carboplatin to an anthracycline/taxane–based chemotherapy regimen in patients with TNBC):
In the GeparSixto trial (NCT01426880), carboplatin was added to an anthracycline/taxane–based backbone.[103][Level of evidence B3]
Source links and citations
In the GeparSixto trial (NCT01426880), carboplatin was added to an anthracycline/taxane–based backbone.[103][Level of evidence B3]
Higher pCR rates were observed with the addition of carboplatin to an anthracycline/taxane–based backbone compared with anthracycline/taxane alone (36.9% vs. 53.2%; P = .005) in patients with TNBC.
In the GeparSixto trial (NCT01426880), carboplatin was added to an anthracycline/taxane–based backbone.[103][Level of evidence B3]
Patients with BRCA1 or BRCA2 variants had a higher rate of pCR, which was not increased by the addition of carboplatin (66.7% in the nonplatinum arm vs. 65.7% in the platinum-containing arm).
In the GeparSixto trial (NCT01426880), carboplatin was added to an anthracycline/taxane–based backbone.[103][Level of evidence B3]
The 3-year DFS rate was higher for patients with TNBC randomly assigned to the carboplatin arm (86.1% vs. 75.8%; HR, 0.56; 95% CI, 0.34−0.93), but OS did not differ.[104]
Source links and citations
In the GeparSixto trial (NCT01426880), carboplatin was added to an anthracycline/taxane–based backbone.[103][Level of evidence B3]
The more intensive regimen was also associated with increased toxicity and treatment discontinuations (39% vs. 48%).
The CALGB 40603 trial (NCT00861705) compared an anthracycline/taxane backbone alone with an anthracycline/taxane backbone plus carboplatin in patients with stage II and stage III TNBC.[105][Level of evidence B3]
Source links and citations
The CALGB 40603 trial (NCT00861705) compared an anthracycline/taxane backbone alone with an anthracycline/taxane backbone plus carboplatin in patients with stage II and stage III TNBC.[105][Level of evidence B3]
The pCR rate for the breast and axilla was 54% for the anthracycline/taxane backbone-plus-carboplatin group versus 41% for the anthracycline/taxane backbone-alone group (P = .0029).
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice